$晶泰控股(0222_老虎社区_美港股上老虎

$晶泰控股(02228)$ 晶泰合作开发的候选药物SIGX1094 1期临床安全性良好，预计2026年第三季度进入2期临床，已获FDA孤儿药资格及快速通道认定

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":585398707262488,"tweetId":"585398707262488","gmtCreate":1783951042071,"gmtModify":1783952535358,"author":{"id":3574483855983034,"idStr":"3574483855983034","authorId":3574483855983034,"authorIdStr":"3574483855983034","name":"行稳致远之","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0},"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","name":"实盘交易者","description":"完成一笔实盘交易","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":27,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02228\">$晶泰控股(02228)$</a> 晶泰合作开发的候选药物SIGX1094 1期临床安全性良好，预计2026年第三季度进入2期临床，已获FDA孤儿药资格及快速通道认定</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02228\">$晶泰控股(02228)$</a> 晶泰合作开发的候选药物SIGX1094 1期临床安全性良好，预计2026年第三季度进入2期临床，已获FDA孤儿药资格及快速通道认定</p></body></html>","text":"$晶泰控股(02228)$ 晶泰合作开发的候选药物SIGX1094 1期临床安全性良好，预计2026年第三季度进入2期临床，已获FDA孤儿药资格及快速通道认定","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/585398707262488","repostId":0,"isVote":1,"tweetType":1,"viewCount":202,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02228"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":126,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}